Empagliflozin in the management of diabetes mellitus after cardiac transplantation
Post-transplant diabetes mellitus (PTDM) is a well-recognised complication of solid organ transplantation.1 PTDM has been associated with increased rates of serious infection, graft rejection and/or dysfunction and reduced long term survival compared to non-diabetic transplant recipients.1 Empagliflozin, a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor, is a novel oral therapy for the management of type 2 diabetes mellitus. When added to standard diabetes care in patients at high cardiovascular risk, empagliflozin is associated with significant reductions in major adverse cardiovascular events, all-cause mortality and hospitalisations for heart failure.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Christopher A. Muir, Jerry R Greenfield, Peter S. MacDonald Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Failure | Heart Transplant | Hospital Management | Jardiance | Lung Transplant | Transplant Surgery | Transplants